Drs. Ron Hoffman and John Mascerenhas of Mt. Sinai School of Medicine in New York have reported positive outcomes from their Phase I trial of panobinostat in myelofibrosis patients. Their article published in the British Journal of Haematology states that significant improvement occurred for patients on low dosages of Panobinostat.
PANOBINOSTAT MF TRIALS PHASE I
MPNRF | April 30, 2021